Hva er årsaken til Parkinsons sykdom?

Dette dokumentet er basert på det profesjonelle dokumentet Parkinsons sykdom (PS). Referanselisten for dette dokumentet vises nedenfor.

1. Dietrichs E, Alves G, Ljøstad U, Mygland Å. Parkinsons sykdom. NEL Nevrologi. Sist revidert 07.11.2017. nevro.legehandboka.no
2. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. pmid:25904081 PubMed 
3. Handlingsplan for Parkinsons sykdom. Revidert juli 2012. Anbefalinger fra Nasjonalt kompetansesenter for bevegelsesforstyrrelser. helse-stavanger.no 
4. Widner H. Parkinsons sjukdom. Senast reviderad 21.06.2017. MEDIBAS kunskapsstöd för hälso- och sjukvård. medibas.se
5. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-35. PubMed 
6. Zhang Q, Chen W, Tan S, Lin T. Stem Cells for Modeling and Therapy of Parkinson's Disease. Hum Gene Ther 2017; 28(1): 85-98. pmid:27762639 PubMed 
7. Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548-560. PubMed 
8. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland, 1817. archive.org 
9. Bega D. Parkinson's disease. BMJ Best Practice. Last updated 02.07.2018. bestpractice.bmj.com 
10. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010;16(2):79-84. PubMed 
11. Espay AJ, Okun MS. Abandoning the Proteinopathy Paradigm in Parkinson Disease. JAMA Neurol 2023; 80: 123-124. doi:10.1001/jamaneurol.2022.4193 DOI 
12. Jankovic J. Etiology and pathogenesis of Parkinson disease. UpToDate, last updated Dec 21, 2021. UpToDate 
13. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361(17): 1651-61. Pmid: 19846850 PubMed 
14. Goldman SM, Tanner CM, Oakes D, et al. Head injury and Parkinson's disease risk in twins. Ann Neurol 2006; 60(1): 65-72. pmid:16718702 PubMed 
15. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71(6): 776-84. pmid:22083847 PubMed 
16. Schrag A, Bohlken J, Dammertz L, et al. Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. JAMA Neurol. Published online November 07, 2022. PMID: 36342675 PubMed 
17. Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol. 2014 Sep;29(9):613-9. Epub 2014 Jun 4. PMID: 24894826. PubMed 
18. Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020; 91:795. PubMed 
19. Shen C, Guo Y, Luo W, et al. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 2013; 40(1): 73-9. pmid:23250131 PubMed 
20. Veiledende retningslinjer for diagnostisering og behandling ved Parkinsons sykdom. Revidert 04/2010. Anbefalinger fra Nasjonalt kompetansesenter for bevegelsesforstyrrelser. www.sus.no/nkb helse-stavanger.no 
21. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30(12): 1591-601. pmid:26474316 PubMed 
22. Brumberg J, Schröter N, Blazhenets G, et al. Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. NPJ Parkinsons Dis. 2020;6(1):39. Published 2020 Dec 11. PMID: 33311476. PubMed 
23. Chou KL. Diagnosis and differential diagnosis of Parkinson disease. UpToDate. Sist oppdatert 05.09.2018. www.uptodate.com 
24. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5(1): 75. pmid:16361025 PubMed 
25. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, Pellecchia MT, Barone P.. The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. Eur J Neurol. 2016 Nov;23(11):1673-1679 . pmid:27435448 PubMed 
26. Aasly JO. Parkinsons sykdom (paralysis agitans) og parkinsonisme. Norsk legemiddelhåndbok, sist oppdatert 17.10.2017. legemiddelhandboka.no 
27. Scott BM, Eisinger RS, Burns MR, et al. Co-occurrence of apathy and impulse control disorders in Parkinson disease. Neurology. 2020;95(20):e2769-e2780. PMID: 33004605 PubMed 
28. Egan SJ, Laidlaw K, Starkstein S. Cognitive Behaviour Therapy for Depression and Anxiety in Parkinson's Disease. J Parkinsons Dis 2015; 5(3): 443-51. pmid:26406124 PubMed 
29. Aarsland D, Pedersen KF, Ehrt U et al. Nevropsykiatriske og kognitive symptomer ved Parkinsons sykdom. Tidsskr Nor Legeforen 2008; 128: 2072-6. Tidsskrift for Den norske legeforening 
30. Clarke CE. Parkinson's disease. BMJ 2007; 335: 441-5. PubMed 
31. Hiort YH, Pedersen KF, Dalen I, et al. Orthostatic hypotension in Parkinson disease A 7-year prospective population-based study. Neurology 2019; 93: 1526-34. pmid:31527282 PubMed 
32. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014 May 20;82(20):1791-7 . pmid:24759846 PubMed 
33. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS corrected recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013; 20(1): 16-34. pmid:23279440 PubMed 
34. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20(1): 5-15. pmid:23279439 PubMed 
35. Bahr R, Karlsson J, Ståhle A, et al. Aktivitetshåndboken (IS-1592): Kap. 36: Parkinsons sykdom. Fagbokforlaget: Helsedirektoratet, 2009. helsedirektoratet.no 
36. Tambosco L, Percebois-Macadré L, Rapin A, et al. Effort training in Parkinson's disease: a systematic review. Ann Phys Rehabil Med. 2014 Mar;57(2):79-104. PMID: 24582335 PubMed 
37. Uhrbrand A, Stenager E, Pedersen MS, et al. Parkinson's disease and intensive exercise therapy - a systematic review and meta-analysis of randomized controlled trials.. J Neurol Sci. 2015; 353(1-2): 9-19. pmid:25936252 PubMed 
38. Shu HF, Yang T, Yu SX, et al. Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.PLoS One. 2014 Jul 1;9(7):e100503. PMID: 24983753. PubMed 
39. Roeder L, Costello JT, Smith SS, et al. Effects of Resistance Training on Measures of Muscular Strength in People with Parkinson's Disease: A Systematic Review and Meta-Analysis. PLoS One 2015. pmid:26146840 PubMed 
40. Mehrholz J, Kugler J, Storch A, et al. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev. 2015 Aug 22;8:CD007830. DOI: 10.1002/14651858.CD007830.pub4 DOI 
41. Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.. Lancet Neurol. 2016 Aug;15(9):954-66. pmid:27478953 PubMed 
42. Tarsy D. Pharmacologic treatment of Parkinson disease. UpToDate. Literature review current through: Oct 2018. Topic last updated: Jul 10, 2018. www.uptodate.com 
43. Garcia-Ruiz PJ. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. Front Neurol. 2018;9:1041. Published 2018 Dec 6. PMID: 30574117 PubMed 
44. Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf. 2018;41(1):19-75. PMID: 28861870 PubMed 
45. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014; Aug;85. pmid:24434037 PubMed 
46. Spindler MA, Hurtig HI. Initial pharmacologic treatment of Parkinson disease. UpToDate, last updated Nov 20, 2019. UpToDate 
47. Halli-Tierney AD, Luker J, Carroll DG. Parkinson Disease. Am Fam Physician. 2020;102(11):679-691. PubMed 
48. Aradi SD, Hauser RA. Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics. 2020;17(4):1339-1365. PubMed 
49. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-78. New England Journal of Medicine 
50. Pålhagen S, Heinonen E, Hägglund J and the Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 2006; 66: 1200-6. Neurology 
51. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-6. Neurology 
52. Odin P, Ray Chaudhuri K, Slevin JT, et al. National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44. pmid:26233582 PubMed 
53. Vitek JL, Jain R, Chen L, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Lancet Neurol 2020; 19:491. PMID: 32470421 PubMed 
54. Lilleeng B, Gjerstad M, Baardsen R, et al. The long-term development of non-motor problems after STN-DBS. Acta Neurol Scand. 2015 Oct;132(4):251-8. pmid:25752590 PubMed 
55. Martinez-Fernandez R, Pelissier P, Quesada JL, et al. Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2016; 87(3): 311-8. pmid:25934016 PubMed 
56. Seppi K, Ray Chaudhuri K, Coelho M et al. The collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: Mov Disord. 2019 May;34(5):765. PMID: 30653247 PubMed 
57. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; : 10.1212/WNL.0b013e3182516244.
58. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20(10): 1255-63. pmid:16041803 PubMed 
59. Rodnitzky RL. Cognitive impairment and dementia in Parkinson disease. UpToDate, last updated Apr 15, 2020. UpToDate 
60. Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson`s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):767-73. Pmid: 25224676.
61. Nasjonal faglig retningslinje om demens. Helsedirektoratet. Utgitt 18.08.2017. IS-2658. V3.1 publisert 17.12.2017. helsedirektoratet.no 
62. Stefani A, Högl B. Sleep in Parkinson's disease. Neuropsychopharmacology. 2020;45(1):121-128. PubMed 
63. Ylikoski A, Martikainen K, Sarkanen T, Partinen M. Parkinson's disease and narcolepsy-like symptoms. Sleepmedicine. Published Online: January 23, 2015 . doi:http://dx.doi.org/10.1016/j.sleep.2014.12.010
64. Asahina M, Vichayanrat E, Low DA, et al. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry 2013; 84: 674-80. PMID: 22942216 PubMed 
65. Pena JIbarretxe-Bilbao NGarcia-Gorostiaga I, et al. Improving functional disability and cognition in Parkinson disease: Randomized controlled trial. Neurology. 2014 Oct 31. pii: 10.1212/WNL.0000000000001043 .
66. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016; 15(12): 1257-1272. pmid:27751556 PubMed 
67. Leung IH, Walton CC, Hallock H, et al. Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology 2015. PMID: 26519540 PubMed 
68. Dahm, K. Reinar, L M. Effekten av fysioterapi for pasienter med Parkinsons sykdom. Rapport fra Kunnskapssenteret nr 21 - 2009.
69. Kordower JH. Gene therapy for Parkinson's disease: still a hot topic?. Neuropsychopharmacology 2015; 40(1): 255-6. pmid:25482182 PubMed 
70. Morizane A, Takahashi J. Cell therapy for Parkinson's disease. Neurol Med Chir (Tokyo) 2016; 56(3): 102-109. pmid:26912295 PubMed 
71. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018 Aug; 33(8): 1248-1266. pmid:29570866 PubMed 
72. Hu XW, Qin SM, Li D, et al. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta Neurol Scand 2013; 128(2): 73-82. pmid:23432663 PubMed 
73. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson`s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013 Jul 23. PMID: 23781007. PubMed 
74. Morgan JC, Currie LJ, Harrison MB, et al. Mortality in levodopa-treated Parkinson's disease. Parkinsons Dis 2014; 2014: 426976. pmid:24616821 PubMed